CBL Dysregulation in Cancer: Mechanisms of Oncogenic Signaling and Therapeutic Potential.

Authors

Andrea J Tench, C Jane McGlade

Published in

Molecular and cellular biology. Pages 1-21. Oct 23, 2026. Epub Oct 23, 2026.

Abstract

CBL is a multifunctional protein with E3 ubiquitin ligase and adaptor capacities, critical to regulating tyrosine kinase signaling pathways. CBL mutations have been identified and most widely characterized in myeloid malignancies, while alterations in solid tumors have also been found. Given its essential role in signaling regulation, disrupted CBL function contributes to oncogenesis and tumor progression. Here we review the mechanisms of CBL dysregulation in cancer, including an overview of mutations identified in leukemias, the impacts of mutant CBL expression on cellular signaling, and how these signaling alterations have been investigated using targeted inhibitors. In addition, CBL mutations identified in solid tumors are described, as well as the mechanisms underlying dysregulation of wild-type CBL function in several malignancies. A consolidated molecular view of disrupted CBL function in cancer is detailed, concluding with descriptions of preclinical approaches to modulate CBL function and identified tool compounds that target CBL regulation.

PMID:
42920319
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.